Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Abstract Background Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone recepto...

Full description

Bibliographic Details
Main Authors: Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Breast Cancer Research
Subjects:
HR+/HER2−
Metastatic breast cancer
Palbociclib
Letrozole
Real-world data
Comparative effectiveness
Online Access:https://doi.org/10.1186/s13058-021-01409-8

Internet

https://doi.org/10.1186/s13058-021-01409-8

Similar Items